Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Leases: 2022-2024

Historic Current Leases for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $185,000.

  • Corvus Pharmaceuticals' Current Leases rose 7.06% to $379,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $379,000, marking a year-over-year increase of 7.06%. This contributed to the annual value of $185,000 for FY2024, which is 86.54% down from last year.
  • Corvus Pharmaceuticals' Current Leases amounted to $185,000 in FY2024, which was down 86.54% from $1.4 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Current Leases ranged from a high of $1.4 million in FY2023 and a low of $185,000 during FY2024.
  • Over the past 3 years, Corvus Pharmaceuticals' median Current Leases value was $1.2 million (recorded in 2022), while the average stood at $929,000.
  • Its Current Leases has fluctuated over the past 5 years, first rose by 11.89% in 2023, then crashed by 86.54% in 2024.
  • Corvus Pharmaceuticals' Current Leases (Yearly) stood at $1.2 million in 2022, then grew by 11.89% to $1.4 million in 2023, then plummeted by 86.54% to $185,000 in 2024.